The most striking US insider move in recent filings involves NVDA. Director Mark A. Stevens sold over $300M worth of NVIDIA shares across three transactions filed on September 2. The three sales — worth $98.5M, $67.9M, and $67.2M respectively — took place on August 31 and September 2. Stevens is an independent director, not a C-level executive. No 10b5-1 pre-planned sale flag was visible in the data, making the scale of the disposal noteworthy against the backdrop of NVIDIA's near-record valuation.
Globally, the picture skews heavily toward selling. Japan's Nippon Paper Industries offloaded a $397M stake in LINTEC Corporation, filed September 8. China's Fosun Pharma sold down $296M in Gland Pharma shares across two tranches filed the same date — a continued retreat from its Indian pharma exposure.
On the buy side, the activity is thinner. Li Ning's controlling shareholder Viva China Holdings bought $67M in Li Ning stock in late August — a vote of confidence in the embattled Chinese sportswear brand. JPMorgan also disclosed a $66M buy in Pharmaron Beijing.
Note: The EDGAR Form 4 tables and Schedule 13D activist filing tables were unavailable for direct query this session. US insider data above is sourced from the vendor table and should be treated as indicative. For full SEC-grade precision, the EDGAR first-party data would be required.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
